Recommendations for the Treatment of Systemic Sclerosis: Agreement May Not Translate into Uptake

REFERENCES

1. 1.↵
   1. de Vries-Bouwstra J,
   2. Allanore Y,
   3. Matucci-Cerinic M,
   4. Balbir-Gurman A

   . Worldwide expert agreement on updated recommendations for the treatment of systemic sclerosis. J Rheumatol 2020;47:249–54.

   OpenUrlAbstract/FREE Full Text
2. 2.↵
   1. Kowal-Bielecka O,
   2. Fransen J,
   3. Avouac J,
   4. Becker M,
   5. Kulak A,
   6. Allanore Y,
   7. et al.

   Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis 2017;76:1327–39.

   OpenUrlAbstract/FREE Full Text
3. 3.↵
   1. Pope JE,
   2. Bellamy N,
   3. Seibold JR,
   4. Baron M,
   5. Ellman M,
   6. Carette S,
   7. et al.

   A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma. Arthritis Rheum 2001;44:1351–8.

   OpenUrlCrossRefPubMed
4. 4.↵
   1. van den Hoogen FH,
   2. Boerbooms AM,
   3. Swaak AJ,
   4. Rasker JJ,
   5. van Lier HJ,
   6. van de Putte LB

   . Comparison of methotrexate with placebo in the treatment of systemic sclerosis: a 24 week randomized double-blind trial, followed by a 24 week observational trial. Br J Rheumatol 1996;35:364–72.

   OpenUrlCrossRefPubMed
5. 5.↵
   1. Kowal-Bielecka O,
   2. Landewe R,
   3. Avouac J,
   4. Chwiesko S,
   5. Miniati I,
   6. Czirjak L,
   7. et al.

   EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR). Ann Rheum Dis 2009;68:620–8.

   OpenUrlAbstract/FREE Full Text
6. 6.↵
   1. Walker K,
   2. Pope J;
   3. Scleroderma Clinical Trials Consortium (SCTC);
   4. Canadian Scleroderma Research Group (CSRG)

   . Expert agreement on EULAR/EUSTAR recommendations for the management of systemic sclerosis. J Rheumatol 2011;38:1326–8.

   OpenUrlAbstract/FREE Full Text
7. 7.↵
   1. Fernández-Codina A,
   2. Walker KM,
   3. Pope JE;
   4. Scleroderma Algorithm Group

   . Treatment algorithms for systemic sclerosis according to experts. Arthritis Rheumatol 2018;70:1820–8.

   OpenUrl
8. 8.↵
   1. Walker K,
   2. Pope J

   . Treatment of systemic sclerosis (SSc) complications: what to use when first-line treatment fails. A consensus of SSc experts. Semin Arthritis Rheum 2012;42:42–55.

   OpenUrlCrossRefPubMed
9. 9.↵
   1. McKeown E,
   2. Bykerk VP,
   3. De Leon F,
   4. Bonner A,
   5. Thorne C,
   6. Hitchon CA,
   7. et al;
   8. CATCH Investigators

   . Quality assurance study of the use of preventative therapies in glucocorticoid-induced osteoporosis in early inflammatory arthritis: results from the CATCH cohort. Rheumatology 2012;51:1662–9.

   OpenUrlCrossRefPubMed
10. 10.↵
    1. Reed J,
    2. Pope JE

    . A comparison between general rheumatologists and scleroderma experts with respect to following systemic sclerosis guidelines. Clin Exp Rheumatol 2015;33 (4 Suppl 91):S40–6.

    OpenUrl
11. 11.↵
    1. Pope J,
    2. Harding S,
    3. Khimdas S,
    4. Bonner A;
    5. Canadian Scleroderma Research Group,
    6. Baron M

    . Agreement with guidelines from a large database for management of systemic sclerosis: results from the Canadian Scleroderma Research Group. J Rheumatol 2012;39:524–31.

    OpenUrlAbstract/FREE Full Text
12. 12.↵
    1. Harding S,
    2. Khimdas S,
    3. Bonner A;
    4. Canadian Scleroderma Research Group,
    5. Baron M,
    6. Pope J

    . Best practices in scleroderma: an analysis of practice variability in SSc centers within the Canadian Scleroderma Research Group (CSRG). Clin Exp Rheumatol 2012;2 Suppl 71:S38–43.

    OpenUrl
13. 13.↵
    1. Distler O,
    2. Brown KK,
    3. Distler JHW,
    4. Assassi S,
    5. Maher TM,
    6. Cottin V,
    7. et al.

    Design of a randomised, placebo-controlled clinical trial of nintedanib in patients with systemic sclerosis-associated interstitial lung disease (SENSCISTM). Clin Exp Rheumatol 2017;35 Suppl 106:75–81.

    OpenUrl
14. 14.↵
    1. Distler O,
    2. Highland KB,
    3. Gahlemman M,
    4. Azuma A,
    5. Fischer A,
    6. Mayes MD,
    7. et al;
    8. SENSCIS Trial Investigators

    . Nintedanib for systemic sclerosis-associated interstitial lung disease. N Engl J Med 2019;380:2518–28.

    OpenUrl
15. 15.↵
    Scleroderma Lung Study III - combining pirfenidone with mycophenolate (SLSIII). [Internet. Accessed August 9, 2019.] Available from: clinicaltrials.gov/ct2/show/NCT03221257
16. 16.↵
    The efficacy and safety of initial triple versus initial dual oral combination therapy in patients with newly diagnosed pulmonary arterial hypertension (TRITON). [Internet. Accessed August 9, 2019.] Available from: clinicaltrials.gov/ct2/show/NCT02558231